Építés alatt – nem éles oldal
Belépés
Résztvevőt keres3. fázis

Chronic Pulmonary Aspergillosis and Ambisome Aerosol with Itraconazole

A legfontosabb adatok

Ki végzi
Poitiers University Hospital
Hol
Franciaország37 helyszín, 1 országbanVálassz országot a helyszínekhez
Állapot
Toboroz
Fázis
3. fázis
Résztvevők
224 fő, tervezett
Kezdés
2018. dec. 19.
Várható befejezés
2029. dec.
A vizsgálat típusa
Beavatkozással járó, 2 csoportAz egyik csoport placebót (hatóanyag nélküli szert) kap, összehasonlításként.
A vizsgált kezelések
  • inhaled Ambisome®
  • inhaled placebo
  • Itraconazole
A regiszteradat frissítve
2025. február 20.

Ki vehet részt

Életkor
18 év felett
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 32 feltétel megnézéseKevesebb

Ki vehet részt

  • All adult patients affected with Chronic Pulmonary Aspergillosis (CPA) "de novo" or in relapse (without any history of resistance to itraconazole) combining the following criteria are eligible:
  • Patient with an Aspergillus bronchopulmonary infection, be it cavitary, fibrotic, necrotizing (SIA/Semi Invasive Aspergillosis) or nodular and documented by compatible thoracic CT-scan images
  • Associated with one of the following criteria:; positive detection of anti-Aspergillus IgG and/or precipitating anti-aspergillus antibodies, according to the positivity threshold of the laboratory performing the technique,; positive direct examination of Aspergillus or positive culture, from bronchopulmonary samples (expectoration or endoscopic aspiration),; revealing aspergillar hyphae/filaments on histological samples
  • Men or women age ≥ 18 years
  • For the women of childbearing age: women having a negative serum pregnancy test, having a contraception highly effective and accepting to pursue it during at least the first 12 months of the study
  • Patient legally free and not subject to any custody, guardianship, tutelage or subordination measures
  • Participants must be affiliated to France's Health Care Regime (" Sécurité Sociale ")
  • Free and informed consent signed by each participating patient

Ki nem vehet részt

  • - Patient presenting a contraindication to itraconazole (including all contraindicated co-administrated medications as listed in the itraconazole SmPc, including notably medications with potential to prolong theQT interval)
  • - Patient presenting a contraindication to voriconazole and posaconazole (including all contraindicated coadministrated medications as listed in the SmPc)
  • - Patient having presented complications related to a previous treatment by nebulised LAmB
  • - Patient received an oral (excepted oral Amphotericin B), parenteral or intra-cavity antifungal treatment within the last 2 months
  • - Concomitant use of one or several of treatments contra-indicated with the experimental or non-experimental treatment
  • - Chronic Pulmonary Aspergillosis with indication for surgical intervention within 6 months from the start
  • - Threatening hemoptysis, with impossibility to defer surgical procedures (but patients contraindicated to surgery may be included after resolution of the hemoptysis)
  • - History of hypersensitivity reaction to liposomal amphotericin B or to itraconazole or to any other constituent
  • - Invasive pulmonary Aspergillosis, Allergic Bronchopulmonary Aspergillosis
  • - Tuberculosis or progressive non-tuberculous mycobacteria
  • - Respiratory infection aggravating the underlying CPA (patient may be included after eradication of infection)
  • - Severe renal failure (clearance <30 ml / min)
  • - Hepatic failure with transaminase and alkaline phosphatase values > 5 times normal
  • - Significant abnormality of the blood cell and platelet counts (at the discretion of the investigator)
  • - Ventricular dysfunction such as congestive cardiac failure or history of congestive cardiac failure or patients with risk(s) factors of cardiac arrhythmia or symptomatic arrhythmia with a prolongation of the corrected QT interval > 450 msec in men and 470 msec in women or treated by medication known to prolong QT interval, or prolongation of the corrected QT interval > 450 msec in men and 470 msec in women
  • - Women at age to procreate and not using highly effective contraception, pregnant or breastfeeding women
  • - Patient affected with single aspergilloma
  • - Intolerance to beta2-agonists
  • - Notion of relapse with isolation of an Aspergillus resistant to itraconazole
  • - Patients with Cystic Fibrosis
  • - Immunocompromised patients
  • - Patient refusing to participate
  • - Protected majors in the meaning of the law, non affiliated persons or with no social security scheme, persons deprived of liberty by a judicial or administrative decision, persons staying in a health or social institution, adults under legal protection, and finally patients in emergencies
  • - Patient in exclusion period following participation in another interventional study evaluating antifungals or medicines

Ez a vizsgálat jelenleg itt érhető el: Franciaország.

Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

This study compares the therapeutic (clinical and radiological) efficacy of a six-month treatment by itraconazole and nebulised Ambisome® (liposomal amphotericin B = LAmB) versus treatment by itraconazole alone, in non - or mildly - immunocompromised patients affected by Chronic Pulmonary Aspergillosis (single aspergilloma excluded).

A teljes eredeti leírásKevesebb

• Control arm: Itraconazole 200 mg x 2/day associated with inactive nebulised treatment twice a week during 24 weeks.

• Experimental arm: Itraconazole 200 mg x 2/day associated with nebulised LAmB, at 25 mg twice a week during 24 weeks.

Follow up duration for the patients will be 24 months (12 months minimum) after discontinuation of the treatment being studied.

A vizsgálat 2 csoportja

  • Itraconazole & inhaled placeboPlacebo, összehasonlításként

    Itraconazole 200 mg x 2/day associated with inactive nebulised treatment (isotonic saline) twice a week during 24 weeks.

    Kezelés: inhaled placebo és Itraconazole

  • Itraconazole & inhaled Ambisome®A vizsgált kezelés

    Itraconazole 200 mg x 2/day associated with inhaled liposomal amphotericin B (Ambisome®) at 25 mg twice a week during 24 weeks

    Kezelés: inhaled Ambisome® és Itraconazole

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on és az EU hivatalos vizsgálati nyilvántartásában (CTIS).
Hivatalos cím
Therapeutic Efficacy Comparison of a Six-month Treatment by Itraconazole and Nebulised Ambisome® Versus Treatment by Itraconazole Alone in Non- or Mildly- Immunocompromised Patients with Chronic Pulmonary Aspergillosis: a Prospective, Randomized, Single Blind Study, (single Aspergilloma Excluded)
A regiszteradat frissítve
2025. február 20.